OTC anti-inflammatories split muscle and tendon adaptation in older lifters

Core signal

Two 2010–2011 trial reports from the same cohort of 36 older adults (~64–67 yr) show that 12 weeks of knee extensor resistance training combined with daily OTC COX inhibitors did not blunt the expected adaptations — the direction of effect was the opposite of the prior in vitro and observational expectation embedded in each abstract. In Receipt 1 (10.1152/ajpregu.00611.2010), acetaminophen and ibuprofen increased muscle volume (~12.5% and ~10.9%) and strength (~19 kg gain) more than placebo; COX-1/-2 enzyme content was uninfluenced. Receipt 2 (10.1152/japplphysiol.01348.2010) shows patellar tendon cross-sectional area, deformation, stiffness, and modulus were largely uninfluenced by ibuprofen, while acetaminophen moved tendon mechanics toward greater deformation/lower stiffness.

The 2+2=5 angle

A coupled boundary condition: the muscle signal is positive (drugs amplified volume/strength gains, the inversion of the "COX inhibitors blunt adaptation" hypothesis), while the tendon signal is split — ibuprofen ≈ null on tendon mechanics, acetaminophen pulls tendon properties in a negative direction (–17% stiffness, –20% modulus). The non-obvious bridge is that the same molecule behaves as an anabolic-adjacent signal for muscle and as a compliance-reducing signal for the tendon it must pull against, raising a muscle–tendon mismatch that is invisible if only muscle endpoints are read.

Why this could matter

For any "longevity + resistance training" product, supplement, or programming stack aimed at sarcopenia reversal in adults ~64–67 yr, the receipts frame a testable counter-hypothesis: concomitant OTC analgesic use is not a default negative for muscle outcomes, but the tendon side may be the binding constraint on safe force transfer. A 30- to 36-person, 12-week, double-blind, placebo-controlled setting is the kind of evidence that procurement, coaching apps, and senior-fitness brands may be importing or ignoring without distinguishing muscle from tendon endpoints.

What would break the idea

• Dose translation: 4 g/day acetaminophen and 1.2 g/day ibuprofen are the only doses tested; chronic real-world dosing in older adults is not characterized here.
• A single cohort (n = 36) drives both signals; a 2+2=5 reading collapses if a larger trial reproduces a negative muscle effect.
• The abstracts report no COX-1/-2 protein change with drug, so the muscle-inversion mechanism is unstated in the receipts — labeled here as a hypothesis, not a finding.

Receipts

• 10.1152/ajpregu.00611.2010 — trial report, 12-week knee extensor resistance training, older adults, acetaminophen 4 g/day vs ibuprofen 1.2 g/day vs placebo, n = 36.
• 10.1152/japplphysiol.01348.2010 — trial report, same cohort, in vivo patellar tendon MRI + ultrasonography outcomes.

Safety note

Receipts are trial-level findings in older adults under supervised dosing; do not extrapolate to other ages, doses, or unsupervised chronic use. No clinical advice is provided.